| INTRODUCTION
Alzheimer's disease (AD) is a progressive and neurodegenerative disease characterized by dementia, memory loss, and other cognitive impairments, which affects millions of elder people around the world. [1, 2] Although many factors contribute to this disease, its etiology and pathogenesis remain unclear until now. Studies have shown that several factors, including obvious reduction in cholinergic neurons, [3] accumulation and aggregation of β-amyloid peptide [4] (Aβ), and oxidative stress [5] , play significant roles in the development of AD. [6] These physiological changes in turn lead to the current strategies for the treatment and prevention of AD. Among them, increasing levels of acetylcholine (Ach) through inhibition of cholinesterase (ChEs) have been used most frequently to treat AD. [7] Up to now, several acetylcholinesterase inhibitors such as donepezil, rivastigmine, and galantamine have been approved and widely used for the treatment of AD. [8] There is evidence that two binding sites exist in AChE according to the crystal structure of the AChE of the eel, including the catalytic active site (CAS) and the peripheral anionic site (PAS). [9] Therefore, it is meaningful to design dual-site inhibitors, which can interact with both the CAS and PAS to prevent AD. It has been reported that N-benzyl pyridinium moiety was introduced into a series of aromatic scaffolds and emerged as an essential structure for some inhibitors of AchE [10] ( Figure 1 ). In our previous studies, using donepezil as a template, [11] a series of dual-site AChE inhibitors were synthesized by introducing N-benzyl pyridinium moiety into the natural product XJP (Figure 1 ). Among these compounds, the most potent compound 1 showed good AChE inhibitory activity (IC 50 value: 8.9 nm) and excellent AChE/BuChE selectivity (SI > 230). [11] The structure-activity relationships (SARs) studies demonstrated that benzyl pyridine, 4-isochromanone skeleton, and nitrogen ion were essential for the activity against AChE. Moreover, the activity was maintained or increased by introducing the fluorine or chlorine to the benzyl group. Other groups introduced to the para-position of the benzyl group diminished the inhibitory activity remarkably. However, the effect of methoxy group at 4-isochromanone skeleton on the AChE inhibitory activity was undefined. Besides, the preferred position of fluorine or chlorine on benzyl group and the importance of α,β-unsaturated ketone to the AChE inhibitory activity should be explored logically. Inspired by our previous promising study and preliminary SARs, we embarked on the second-round design to accomplish the SARs and find more potent AChE inhibitors. Herein, a series of novel AChE inhibitors bearing 4-isochromanone moiety were further designed and synthesized using compound 1 as the lead compound. The ChEs inhibitory activities and selectivity of target compounds were also evaluated. Moreover, the neurotoxicity and plasma stability studies of potent compounds were disclosed in this research.
S C H E M E 1
The synthetic route of target compounds was shown in Schemes 1, 2. Based on our previously developed method for the construction of 4-isochromanone with Weinreb amide, [12] we successfully completed the synthesis of 4-isochromanone skeleton to get the compound 7, which reacted with pyridine formaldehyde to yield the intermediate 9 in the presence of K 2 CO 3 . Target compounds 1a-1r were obtained after the nucleophilic substitution of compound 9. The intermediate 9 was hydrogenated with Pd-C as a catalyst at the pressure of 0.7 MPa to afford compound 11, which was oxidized with Dess-Martin oxidizing reagent to yield compound 12. Compounds 1s-1v were obtained by the reaction of compound 12 with various substituted benzyl bromide.
| METHODS AND MATERIALS

| General procedure for preparation of compounds
Compound 9 or 12 was dissolved in acetonitrile, and then, substituted bromobenzene was added. The mixture was refluxed at 80°C for 1 hr. The yellow solid precipitated, and the target compound was obtained by filtration. 
| (Z)-4-((6,7-dimethoxy-
4-oxoisochroman-3-ylidene)methyl)-1-(4-fluorobenzyl)pyridinium bromide (1q)
| (Z)-4-((6,7-dimethoxy-4-oxoisochroman-3-ylidene)methyl)-1-(2-fluorobenzyl)pyridinium bromide (1r)
| AChE and BuChE inhibitory activity test assay
The compound was dissolved in DMSO, diluted with buffer A to the desired concentration, and the DMSO content in the solution was controlled to be <1%. To the 96-well plates were added: 160 μl of 1.5 mm DTNB, 50 μl of AChE (0.22 U/ml, prepared with Buffer B), and 10 μl of different concentrations of inhibitor, incubated at 37°C for 10 min, and then, 30 μl of iodoacetylcholine (15 mm) was added rapidly. The absorbance changes of 0, 60, 120, and 180 s were measured at 405 nm wavelengths. BuchE was tested in an assay similar to AChE, which needed to replace AChE with BuChE (0.12 U/ ml, prepared with Buffer B) and replace substrate iodoacetylcholine with thioiodobenzoyl chloride (15 mm), and other conditions remain unchanged.
S C H E M E 2 Reagents and conditions:
(a) H 2 /Pd-C, 0.7 Mpa, r.t., overnight, 70% yield; (b) Dess-Martin reagent, r.t. 85% yield; (c) CH 3 CN, reflux, 1 hr, 60%-80% yields
| Cell viability
SH-SY5Y cells were planted in a 25-ml culture flask containing 1:1 mixture of Eagle's minimum essential medium (EMEM) and ham's F-12 medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin, placed in a 5% carbon dioxide incubator at 37°C. The cells were then grown at a density of 10,000 per well in 96-well plates. When the cells were fused, the cells were placed in serum-free medium and cultured with different concentrations of compound 1q, 1r (1, 5, 10, 25, 50 μm) for 24 hr. After completion of the incubation, 20 μl of MTT was added at 37°C for 4 hr, and 200 μl of DMSO was added to dissolve methanine crystals at the end, and the absorbance was measured at 570 nm.
| Plasma stability test
A certain amount of compound 1q was dissolved in DMSO, which was adjusted to the equivalent of free base 1.67 mg/ml of the mother liquor according to the purity and salinity, and then using 50% MeOH diluted it to 100 μg/ml of the INT solution. 2 μl of INT solution was taken and mixed with 998 μl plasma (n = 2, the ratio of organic phase in the system does not exceed 0.5%), the concentration of compound in plasma is 200 mg/ml, and it was placed at 37°C water bath incubation. The sampling point was set at 0, 10, 30 min, 1, 2 hr. each sampling point took 100 μl of sample and was added 300 μl acetonitrile to precipitate, then centrifuged at 13450 g for 5 min, and supernatant 100 μl was added 100 μl 0.1% formic acid and took to LC-MS/MS analysis. 
| RESULTS AND DISCUSSION
To determine the inhibitory activities of these target compounds against AChE and BuChE, [13] IC 50 of all compounds was obtained. Lead compound 1 and donepezil were used as the reference compounds, and the results are shown in Table 1 .
It was found that the inhibitory activities of most compounds reached the nanomolar level against AChE and the micromolar level against BuChE. Among them, compound 1q showed the most potent activity against AChE with IC 50 of 0.15 nm, which was 250 and 160 times higher compared to the positive drug donepezil and the lead compound 1, respectively. Furthermore, its selectivity index of AChE/BuChE reached up to 5903. The SARs studies showed that when keeping fluorine group at the para-position of the benzyl group, the anti-AChE activity was enhanced or maintained by introducing halogens to the ortho-position. On the contrast, introducing halogens to the meta-position decreased the activity dramatically. As to compounds 1o-1r, the number and position of the methoxy group on 4-isochromanone skeleton had a significant influence on the anticholinesterase activity. The compounds bearing methoxy group at both R 1 and R 2 positions exhibited more potent anticholinesterase activity than those with methoxy group at both R 2 and R 3 positions. Besides, those compounds with reduced double bond also have good anticholinesterase activity (1s-1v).
| Molecular docking study
To investigate the interaction mode of compounds 1 and 1q with AChE, a molecular modeling study [14] was carried out using Molecular Operating Environment (moe) software and the PDB structure of 1EVE was taken from the RCSB Protein Data Bank for the docking procedure. Previous studies showed that two methoxy groups of donepezil interacted with Trp286 of acetylcholinesterase through hydrogen bond. [15, 16] In the present study, the methoxy group at the C7 position of compound 1 interacted with Trp286 to form a hydrogen bond, while the methoxy group at the C8 position could not form a hydrogen bond with Trp286 due to steric hindrance ( Figure 2b ). However, both methoxy groups of compound 1q could interact with Trp286 through hydrogen bond, which was similar to that of donepezil, and at the same time, according to previous study, phenyl pyridine interacted with the CAS of AChE and the 4-isochromanone moiety interacted with the PAS of the AChE simultaneously. This interaction mode might explain why the activity of compound 1q was significantly increased.
| Cell viability test of compounds 1q and 1r
To measure the toxicity of target compounds against nerve cells, [17] the viability of SH-SY5Y cells treated with representative compounds 1q and 1r was determined and the result is shown in Table 2 . When SH-SY5Y cells were exposed to compounds 1q and 1r at concentrations of 5 and 50 μm for 24 hr, the survival rates of nerve cells did not decrease obviously. Even at the concentration of 100 μm, the survival rate just decreased slightly (cell viability >90%) and the morphology of the cells was not affected, indicating the low toxicity of these compounds.
| Plasma stability test and pharmacokinetic data of compound 1q
Compound 1q has a good inhibitory activity on enzyme, to provide information for pharmacokinetic evaluation, and representative compound 1q was selected for preliminary plasma stability test. The results showed the concentration of compound 1q in plasma decreased with time, but changed slightly in the period of 0-2 hr, indicating that compound 1q was relatively stable in rat plasma ( Table 3) . The further pharmacokinetic evaluation showed that compound 1q had undesirable pharmacokinetic properties and its average half-life was only 1.94 hr (Table 4) . Therefore, compound 1q might be considered as a promising lead for the next round structural modification.
| CONCLUSIONS
In conclusion, a series of novel AChE inhibitors derived from natural product XJP were further designed and synthesized based on our previous studies. The biological evaluation showed that these compounds had potent activities against AChE and good selectivity against BuChE. Among them, compound 1q showed the strongest anti-AChE activity (IC 50 = 0.15 nm), high AChE/BuChE selectivity (SI > 5903), and low neurotoxicity. Additionally, compound 1q possessed high plasma stability. As a result, compound 1q might be considered as a promising lead compound for further research to develop new anti-AD agents. The pharmacokinetic parameters were calculated using winnonlin 5.2. HL, half-life of the drug; T max , the time to reach the peak concentration of drug; C max , peak concentration of drug; AUC, area under the curve, it is an important indicator of the degree of drug absorption; V z , apparent distribution volume; Cl, drug internal clearance rate; MRT, average dwell time.
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